When and How to Adjust Non-Pharmacological Interventions Concurrent with Booster Vaccinations Against COVID-19 — Guangdong, China, 2022

Introduction With the large-scale roll-out of the coronavirus disease 2019 (COVID-19) booster vaccination effort (a vaccine dose given 6 months after completing primary vaccination) in China, we explore when and how China could lift non-pharmacological interventions (NPIs) against COVID-19 in 2022. Methods Using a modified susceptible-infectious-recovered (SIR) mathematical model, we projected the COVID-19 epidemic situation and required medical resources in Guangdong Province, China. Results If the number of people entering from overseas recovers to 20% of the number in 2019, the epidemic in 2022 could be controlled at a low level by a containment (215 local cases) or suppression strategy (1,397 local cases). A mitigation strategy would lead to 21,722 local cases. A coexistence strategy would lead to a large epidemic with 6,850,083 local cases that would overwhelm Guangdong’s medical system. With 50% or 100% recovery of the 2019 level of travelers from overseas, the epidemic could also be controlled with containment or suppression, but enormous resources, including more hotel rooms for border quarantine, will be required. However, coexistence would lead to an uncontrollable epidemic with 12,922,032 local cases. Discussion With booster vaccinations, the number of travelers from overseas could increase slightly in 2022, but a suppression strategy would need to be maintained to ensure a controllable epidemic.

[1]  E. Azziz-Baumgartner,et al.  Incidence of SARS-CoV-2 Infection, Emergency Department Visits, and Hospitalizations Because of COVID-19 Among Persons Aged ≥12 Years, by COVID-19 Vaccination Status — Oregon and Washington, July 4–September 25, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[2]  Z. Ademi,et al.  Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis , 2021, BMJ.

[3]  Weihao Shao,et al.  Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis , 2021, International Journal of Infectious Diseases.

[4]  M. Hernán,et al.  Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study , 2021, The Lancet.

[5]  E. Undurraga,et al.  Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile , 2021, The New England journal of medicine.

[6]  C. Viboud,et al.  Despite vaccination, China needs non-pharmaceutical interventions to prevent widespread outbreaks of COVID-19 in 2021 , 2021, Nature Human Behaviour.

[7]  M. V. Van Kerkhove,et al.  Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[8]  Lisa E. Gralinski,et al.  SARS-CoV-2 Infection is Effectively Treated and Prevented by EIDD-2801 , 2021, Nature.

[9]  Manfred Lenzen,et al.  Global socio-economic losses and environmental gains from the Coronavirus pandemic , 2020, PloS one.

[10]  Xihong Lin,et al.  Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. , 2020, JAMA.